Clinical Trials Browser

INDUSTRY × Nasopharyngeal Carcinoma × Lymphoid × Clear all

Nasopharyngeal Carcinoma, Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin

NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

NCT02822495 2023-06-15

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

No longer available

Head & NeckLymphoidSarcoma

Nasopharyngeal Carcinoma, Primary Immunodeficiency Diseases, Arthritis, Rheumatoid, Infections, Leiomyosarcoma, Lymphoma, Lymphoproliferative Disorders, Inflammatory Bowel Diseases, Lymphoma, AIDS-Related, Epstein-Barr Virus Infections

NCT05415098 2022-11-16

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Phase 1 Unknown

90 enrolled

GastrointestinalHead & NeckLymphoidOther solid neoplasmSarcomaThoracic

Nasopharyngeal Carcinoma, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Stomach Neoplasms, Lymphoma, B-Cell

Clinical Trials

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas